Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC)
CUSIP: 816212302
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 26,658,100
- Total 13F shares
- 6,401,037
- Share change
- -181,400
- Total reported value
- $66,468,780
- Price per share
- $10.39
- Number of holders
- 65
- Value change
- -$2,049,017
- Number of buys
- 28
- Number of sells
- 29
Quarterly Holders Quick Answers
What is CUSIP 816212302?
CUSIP 816212302 identifies RNAC - Cartesian Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 816212302:
Top shareholders of RNAC - Cartesian Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Timothy A. Springer |
13D/G
|
— |
37%
|
9,555,394
|
$116,671,361 | +$258,583 | 13 Jan 2025 | |
| FMR LLC |
13F
|
Company |
8.8%
|
2,339,917
|
$30,840,106 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13D/G
13F
|
Company |
6.1%
|
1,675,636
|
$20,459,516 | $0 | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
3%
|
790,779
|
$10,422,467 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.5%
|
673,050
|
$8,870,803 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
2.1%
|
563,272
|
$7,423,925 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.9%
|
503,537
|
$6,636,617 | — | 31 Mar 2025 | |
| Erste Asset Management GmbH |
13F
|
Company |
0.98%
|
260,011
|
$3,431,795 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.85%
|
225,500
|
$2,972,650 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.75%
|
201,125
|
$2,650,828 | — | 31 Mar 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.56%
|
150,000
|
$1,977,000 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.55%
|
147,297
|
$1,941,374 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.35%
|
92,337
|
$1,217,002 | — | 31 Mar 2025 | |
| Metin Kurtoglu |
3/4/5
|
Chief Technology Officer |
—
mixed-class rows
|
188,757
mixed-class rows
|
$1,110,427 | — | 03 Jan 2025 | |
| Peter G. Traber |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
451,826
|
$930,762 | — | 25 Sep 2023 | |
| Lloyd P. Johnston |
3/4/5
|
Chief Operations Officer |
—
mixed-class rows
|
740,515
mixed-class rows
|
$922,211 | — | 04 Jan 2023 | |
| Aymeric Sallin |
3/4/5
|
Director |
—
mixed-class rows
|
406,000
mixed-class rows
|
$546,800 | — | 02 Jan 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.14%
|
38,605
|
$508,814 | — | 31 Mar 2025 | |
| Takashi Kei Kishimoto |
3/4/5
|
Chief Scientific Officer |
—
class O/S missing
|
225,316
|
$464,151 | — | 30 May 2023 | |
| Kevin Tan |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
417,000
mixed-class rows
|
$427,220 | — | 03 Jan 2022 | |
| UBS Group AG |
13F
|
Company |
0.12%
|
31,118
|
$410,135 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.11%
|
29,303
|
$386,214 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.1%
|
27,869
|
$367,313 | — | 31 Mar 2025 | |
| Freestone Capital Holdings, LLC |
13F
|
Company |
0.1%
|
25,921
|
$341,639 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.08%
|
22,166
|
$292,149 | — | 31 Mar 2025 | |
| DELPHI FINANCIAL GROUP, INC. |
13F
|
Company |
0.08%
|
22,028
|
$290,329 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.08%
|
20,937
|
$275,950 | — | 31 Mar 2025 | |
| ALPS ADVISORS INC |
13F
|
Company |
0.07%
|
19,392
|
$255,587 | — | 31 Mar 2025 | |
| Christopher M. Jewell |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
177,322
mixed-class rows
|
$255,114 | — | 10 Jan 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.07%
|
17,850
|
$235,264 | — | 31 Mar 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.06%
|
16,791
|
$221,000 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.06%
|
15,775
|
$207,915 | — | 31 Mar 2025 | |
| TWIN FOCUS CAPITAL PARTNERS, LLC |
13F
|
Company |
0.06%
|
15,000
|
$197,700 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.05%
|
14,369
|
$189,384 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.05%
|
13,006
|
$171,409 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.05%
|
12,460
|
$164,223 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.04%
|
11,015
|
$145,178 | — | 31 Mar 2025 | |
| Virtus Investment Advisers, LLC |
13F
|
Company |
0.03%
|
8,160
|
$107,549 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
7,708
|
$101,592 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.03%
|
7,424
|
$97,848 | — | 31 Mar 2025 | |
| AlphaQuest LLC |
13F
|
Company |
0.03%
|
7,191
|
$94,777 | — | 31 Mar 2025 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.03%
|
6,667
|
$87,871 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.02%
|
6,020
|
$79,344 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.02%
|
5,981
|
$78,829 | — | 31 Mar 2025 | |
| China Universal Asset Management Co., Ltd. |
13F
|
Company |
0.02%
|
5,098
|
$67,192 | — | 31 Mar 2025 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.02%
|
5,047
|
$66,519 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
4,955
|
$65,307 | — | 31 Mar 2025 | |
| Goran Ando |
3/4/5
|
Director |
—
class O/S missing
|
75,000
|
$59,250 | — | 02 Jan 2023 | |
| Carrie S. Cox |
3/4/5
|
Director |
—
mixed-class rows
|
23,629
mixed-class rows
|
$57,896 | — | 02 Jan 2025 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.01%
|
3,902
|
$51,428 | — | 31 Mar 2025 |
Institutional Holders of Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) as of Q2 2025
As of 30 Jun 2025,
Cartesian Therapeutics, Inc. - COMMON STOCK (RNAC) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,401,037 shares.
The largest 10 holders included
FMR LLC, MPM BIOIMPACT LLC, BlackRock, Inc., Siren, L.L.C., VANGUARD GROUP INC, Erste Asset Management GmbH, 683 Capital Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, and CITADEL ADVISORS LLC.
This page lists
65
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
68
Q2 2025 holders
65
Holder diff
-3
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.